Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Thymoma
ADR ID BADD_A07756
ADR Hierarchy
01      Blood and lymphatic system disorders
01.09      Spleen, lymphatic and reticuloendothelial system disorders
01.09.04      Thymus disorders
01.09.04.003      Thymoma
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.19      Respiratory and mediastinal neoplasms malignant and unspecified
16.19.07      Mediastinal neoplasms malignancy unspecified NEC
16.19.07.002      Thymoma
22      Respiratory, thoracic and mediastinal disorders
22.09      Thoracic disorders (excl lung and pleura)
22.09.03      Mediastinal disorders
22.09.03.010      Thymoma
Description A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed) [MeSH]
MedDRA Code 10043670
MeSH ID D013945
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Thymoma | Thymoma NOS | Thymomas | Carcinoma, Thymic | Carcinomas, Thymic | Thymic Carcinoma | Thymic Carcinomas
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01599Olanzapine0.000316%
BADD_D02464Fingolimod0.000241%
The 1th Page    1    Total 1 Pages